Dynavax Technologies Co. (NASDAQ:DVAX) Director Francis Cano Sells 3,615 Shares

Dynavax Technologies Co. (NASDAQ:DVAXGet Free Report) Director Francis Cano sold 3,615 shares of the company’s stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $11.93, for a total value of $43,126.95. Following the sale, the director now owns 36,905 shares of the company’s stock, valued at approximately $440,276.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Dynavax Technologies Trading Up 2.8 %

NASDAQ:DVAX opened at $12.32 on Tuesday. The stock has a fifty day moving average price of $11.69 and a two-hundred day moving average price of $12.72. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of 205.33 and a beta of 1.20. The company has a debt-to-equity ratio of 0.36, a quick ratio of 14.10 and a current ratio of 15.20. Dynavax Technologies Co. has a 1 year low of $10.48 and a 1 year high of $15.15.

Dynavax Technologies (NASDAQ:DVAXGet Free Report) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). Dynavax Technologies had a net margin of 3.91% and a return on equity of 1.52%. The firm had revenue of $50.79 million during the quarter, compared to analysts’ expectations of $51.98 million. As a group, sell-side analysts anticipate that Dynavax Technologies Co. will post 0.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on DVAX shares. StockNews.com cut Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, May 28th. William Blair reiterated an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 23rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $29.00 price objective on shares of Dynavax Technologies in a research report on Thursday, May 9th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $25.33.

Get Our Latest Analysis on Dynavax Technologies

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. SummerHaven Investment Management LLC increased its position in shares of Dynavax Technologies by 1.5% in the fourth quarter. SummerHaven Investment Management LLC now owns 52,973 shares of the biopharmaceutical company’s stock valued at $741,000 after buying an additional 799 shares in the last quarter. Congress Asset Management Co. MA increased its position in shares of Dynavax Technologies by 0.4% in the fourth quarter. Congress Asset Management Co. MA now owns 227,135 shares of the biopharmaceutical company’s stock valued at $3,175,000 after buying an additional 799 shares in the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Dynavax Technologies by 1.5% during the fourth quarter. Exchange Traded Concepts LLC now owns 57,593 shares of the biopharmaceutical company’s stock valued at $805,000 after acquiring an additional 828 shares during the last quarter. Handelsbanken Fonder AB boosted its stake in shares of Dynavax Technologies by 3.4% during the fourth quarter. Handelsbanken Fonder AB now owns 27,300 shares of the biopharmaceutical company’s stock valued at $382,000 after acquiring an additional 900 shares during the last quarter. Finally, Diversified Trust Co boosted its stake in shares of Dynavax Technologies by 3.2% during the first quarter. Diversified Trust Co now owns 29,548 shares of the biopharmaceutical company’s stock valued at $367,000 after acquiring an additional 925 shares during the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

About Dynavax Technologies

(Get Free Report)

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

Featured Stories

Insider Buying and Selling by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.